Autoimmune CAR T advances amid emerging safety concerns

A Nature Medicine clinical-pipeline feature reviews early CAR T cell studies in autoimmune disease and recent safety-related trial pauses. Small studies report disease control, but serious toxicities, limited long-term evidence and treatment burdens remain concerns as development expands.

22 of 24 adults had disease control for at least 24 weeks.
Pooled lupus analysis found remission in 70%.
Two companies paused autoimmune CAR T studies over safety concerns.
Long-term safety and routine-care benefits remain uncertain.

CD19-targeting CAR T cell therapy has moved from isolated reports in severe systemic lupus erythematosus into early clinical development across autoimmune diseases. The feature describes a phase 1/2 basket trial in 24 adults with severe disease, including lupus and systemic sclerosis, and a separate pooled analysis of 145 lupus patients across 16 studies. Most trials in the field are phase 1 or 2, according to the article.

In the Erlangen basket trial, 22 of 24 participants had drug-free disease control for at least 24 weeks; no cases of immune effector cell-associated neurotoxicity syndrome (ICANS) or severe cytokine-release syndrome were reported. The pooled analysis found remission in 70% of patients with lupus. Eleven participants (7.6%) developed serious infections, including one fatal pneumococcal meningitis. Separately, Novartis paused multiple rapcabtagene autoleucel autoimmune trials after reported deaths associated with immune effector cell-associated hemophagocytic syndrome; Bristol Myers Squibb paused enrollment and treatment in zolacabtagene autoleucel studies after increased ICANS in a phase 2 trial.

These findings are preliminary and do not establish long-term benefit or safety in routine care. CAR T treatment involves cell collection, manufacturing and lymphodepleting chemotherapy, and may require prolonged safety monitoring. The feature emphasizes that evidence, treatment protocols and toxicity risks vary, and that benefits must be weighed against established options, particularly for patients whose disease is controlled with existing therapies.

In practice

For patients with severe, treatment-refractory autoimmune disease, early studies suggest CD19-targeting CAR T cells can produce drug-free disease control, but this evidence does not establish a role in routine care or justify replacing effective existing treatment. Small and early studies provide limited information on durability and uncommon harms; serious infections and other severe toxicities have been reported, and trials have been paused for safety reviews. Treatment also entails cell manufacturing, lymphodepleting chemotherapy and potentially prolonged monitoring.

AI-generated clinical interpretation · Not editor-reviewed

AI summary · Not yet editor-reviewed

Is this summary clinically accurate?

Help fellow clinicians: your rating sends inaccurate summaries straight to our editors.

Source

Nature Medicine: A reality check for autoimmune CAR T cells ↗

This is an automated AI-condensed summary that has not yet been reviewed by an editor. Always consult the full item at the original source.